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EDITORIAL
Defining the immunogram of breast cancer: a focus on clinical trials
Paolo Tarantino and Giuseppe Curigliano
Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and
Haematology (DIPO), University of Milan, Milan, Italy
ABSTRACT
In phase III ImPassion130 trial, the addition of immunotherapy to chemotherapy improved overall
survival in metastatic triple-negative breast cancer patients. This benefit was significant only in patients
harboring PD-L1-positive tumors, suggesting that stratification according to response biomarkers is
needed to achieve consistent responses. Besides PD-L1 expression, a variety of potential biomarkers are
under investigation for predicting immunotherapy efficacy in breast cancer, such as tumor-infiltrating
lymphocytes, gene signatures, tumor mutational burden, microsatellite instability, and gut microbiome.
Enriching future trials through these biomarkers could help identifying the population of responders,
realizing what has been called precision immunotherapy.
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The results of the recently published phase III ImPassion130 trial
bring breast cancer (BC) in the immunotherapy era. Schmid and
colleagues demonstrated a substantial overall survival (OS) gain
in PD-L1-positive metastatic triple-negative breast cancer
(mTNBC) patients by the addition of the anti-PD-L1 agent atezo-
lizumab to first-line chemotherapy with nab-paclitaxel [1].
Median OS was prolonged by nearly 10 months compared to
chemotherapy arm. Results from this trial led to the recent FDA
approval of atezolizumab for adult patients with advanced TNBC
whose tumors express PD-L1 [2].
According to these data, is immunotherapy transformative
for metastatic TNBC? Many open questions arise from the trial.
How best to test the tumor for PD-L1 expression since this
subgroup of patients derived benefit from atezolizumab? Is
nab-paclitaxel the ideal partner for an immune checkpoint
inhibitor? Did we miss an atezolizumab monotherapy arm
that might be a good option for a subset of patients? Should
we be more focused on OS rather than PFS? What can we
learn from the neoadjuvant setting?
Such a positive result was achieved by stratifying patients
according to PD-L1 expression, which allowed to identify a
population deriving greater benefit from immunotherapy.
Stratifying patients based on predictive markers allows to
increase benefit from experimental treatments. Therefore, the
definition of an ‘immunogram’ of patients with BC will be key
for the design of future clinical trials.
Besides PD-L1 expression, a variety of potential biomarkers
are under investigation for predicting immunotherapy efficacy in
BC. A conceptualization of the comprehensive view of immu-
notherapy in cancer treatment has been proposed earlier,
included in the framework of the cancer immunogram [3]. Since
then, interesting evidence has emerged fromBC immunotherapy
trials regarding predictive biomarkers, and a specific breast can-
cer immunogram can be proposed. The presence of tumor-
infiltrating lymphocytes (TILs), a known prognostic factor in
early TNBC, showed a predictive value in TNBC patients treated
with immune-checkpoint-inhibitors (ICI) monotherapy [4] and is
now being implemented as a stratification factor in BC immu-
notherapy trials. Interestingly, in the ImPassion130 trial, TILs were
predictive of ICI efficacy only in PD-L1-positive tumors, showing
that a multidimensional immunogram has a better predictive
potential compared with a single factor [5]. In fact, since tumoral
PD-L1 expression is induced by IFN-γ [6], TILs found in PD-L1-
negative tumors are not expected to be secreting IFN-γ, thus
most likely not exerting antitumoral activity. Indeed, a recent
characterization of BC TILs suggested that a significant part of
these should be considered bystander T cells, explaining the
lower activity of ICI in this population compared with more
immunogenic tumors [7].
Together with TILs, multiple gene signatures have been
studied as a surrogate of BC immunogenicity, including the
recent proposal of classifying BC into four categories (immu-
nologic constant of rejection, ICR1-4) according to their
immune-related gene expression, classes which have been
shown to correlate with survival in a retrospective in-silico
simulation [8]. Nonetheless, the presence of TILs and immune
signatures does not seem to guarantee the existence of an
immune response, which also requires the presence of immu-
nogenic tumor-associated antigens and neo-antigens to be
efficient. As an estimate of neo-antigen expression, tumor
mutational burden was recently proved to identify those
patients across BC subtypes with more chance to derive ben-
efit from ICI therapy [9]; however, a prospective confirmation
is still awaited. One particular condition producing genetic
instability and increased neo-antigen formation is the case of
microsatellite-unstable tumors, which account for a small per-
centage of BC, but which predict response to ICI [10]. Lastly,
the evidence is arising regarding the effect of the gut
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microbiome in ICI response, although more studies are
needed to define its role in clinical practice [11].
The abovementioned biomarkers should not be interpreted
as interchangeable, but complementary, since each describes
a feature of the complex cancer–immune interaction. They
could, therefore, help in enriching study populations, provid-
ing the rationale and the tools to design precision immunother-
apy trials (Figure 1).
IO: immunotherapeutical agent; CT: chemotherapy; AbDC:
antibody–drug conjugate; PARP-i: poly-ADP-ribose-polymerase
inhibitor.
Expert opinion: In the scenario of BC immune-oncology
trials (Table 1), the multiplicity of BC subtypes and disease
settings constitute both a matter of complexity and
opportunity.
As previouslymentioned, immunogenicity differs between BC
subtypes, with TNBC generally being more immunogenic than
HER2+ and luminal cancers; nevertheless, each subtype provides
specific treatment modalities to be potentially combinedwith ICI
to boost their activity. In HER2+ BC, a variety of anti-HER2 agents
are currently administered in each disease setting, providing the
rationale for immuno-anti HER2 combination therapies. And
indeed, some recent data show that adding ICI to anti-HER2
could revert resistance to targeted therapy and induce promising
responses [12]. Moreover, in analogy with other oncogene-dri-
ven tumors, HER2 amplification was found to reduce tumor
immunogenicity by interfering with antigen presentation [13];
thus, anti-HER2 treatment could support ICI efficacy. Therefore,
ICI and anti-HER2 agents could prove synergistic in the treatment
of these tumors. Luminal cancers, on the other hand, typically
benefit of endocrine therapy and are less responsive to ICI; none-
theless, strategies are being studied to improve ICI efficacy in this
context, by patient enrichment and by priming the tumor with
immune attractants [14]. In both cases, finding the most promis-
ing combinations and identifying responders through biomarker
enrichment remain the preeminent challenges for immune-
oncology trials.
LA: locally advanced; NACT: neoadjuvant chemotherapy;
ACT: adjuvant chemotherapy.
Regarding the disease setting, each bears its peculiarities
and each could potentially benefit from ICI addition. The
metastatic setting was the first to be explored, and some
lessons were learned by phase I trials: first, that ICI should be
combined with other agents in order to improve benefit for
most of the patients; second, that immunotherapy should be
Figure 1. Proposal for a precision immunotherapy trial strategy in mTNBC.
Table 1. Examples of ongoing randomized immunotherapy trials in breast
cancer.
Setting Phase Regimen Population Trial
Neoadjuvant III Doxorubicin +
cyclophosphamide
nab-paclitaxel ±
atezolizumab
TNBC NCT03197935
Neoadjuvant III Carboplatin +
paclitaxel +
(anthracycline) +
cyclophosphamide
± pembrolizumab
TNBC NCT03036488
Neoadjuvant II Nab-paclitaxel +
epirubicin +
cyclophosphamide
± durvalumab
TNBC NCT02685059
Adjuvant III Paclitaxel +
doxorubicin +
cyclophosphamide
± atezolizumab
TNBC NCT03498716
Adjuvant III Pembrolizumab TNBC with
residual
disease after
NACT
NCT02954874
Adjuvant III Avelumab High-risk TNBC
(after NACT
or standard
ACT)
NCT02926196
Metastatic/
LA
III Paclitaxel ±
atezolizumab
TNBC
(first line)
NCT03125902
Metastatic/
LA
III (Chemotherapy) +
pembrolizumab
TNBC
(first line)
NCT02819518
Metastatic/
LA
III Paxlitaxel +
trastuzumab+
pertuzumab ±
atezolizumab
HER2+ BC
(first line)
NCT03199885
Metastatic/
LA
II Eribulin ±
pembrolizumab
HR+ HER2- BC
(late line)
NCT03051659
Metastatic/
LA
II Olaparib ±
atezolizumab
BRCA-mut
HER2- BC
(late line)
NCT02849496
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implemented in the first line of metastatic treatment to
improve response rates; third, that patients should be strati-
fied according to specific biomarkers. Early BC setting appears
to be even more appealing for ICI introduction, both in the
neoadjuvant and adjuvant setting, since primary tumors seem
to be more immunogenic than metastasis [15]. In the adjuvant
setting, we believe that patients at high risk for relapse, less
likely to be cured by current standard treatments, are the ones
who could potentially benefit the most by ICI addition. For
instance, TNBC patients not achieving pCR after neoadjuvant
chemotherapy are known to have a worse prognosis, and
capecitabine administration is the only standard of care for
these patients [16]. ICI addition could improve cure rates in
this setting, and some trials (eg. A-BRAVE trial [17]) are explor-
ing this possibility. Combining the risk profile with immune
response biomarkers promises to precisely define the popula-
tion for early BC immunotherapy trials.
Overall, it is an exciting time for breast oncology. Results are
awaited from immune-oncology trials studying various combina-
tions and strategies, including a whole new upcoming genera-
tion of immune checkpoint inhibitors [18]. These trials will
hopefully shed light on BC immuno-response biomarkers and
define if a multidimensional immunogram could be better in
predicting efficacy than the current PD-L1-based unidimensional
immunogram. The expanding knowledge on BC immune land-
scape might soon help tailoring immunotherapy, enabling us to
unleash the power of these agents in selected patients more
likely to respond and get long-lasting benefit, leading to a new
era of precision BC immunotherapy.
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